JAZZ250516C115000
- 5.80
- +1.39+31.52%
Jazz Pharmaceuticals Newsroom
With A 14% Return On Equity, Is Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) A Quality Stock?
RBC Capital Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $182
Jazz Pharmaceuticals (JAZZ) Gets a Buy From RBC Capital
Jazz Pharmaceuticals | 10-K/A: Annual report (Amendment)
PTC and Jazz Pharmaceuticals Among Latest Firms to Win EU Backing for Drugs
Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
Express News | RPT-EMA Says Sephience (Sepiapterin) Got Positive Opinion From Chmp for Treatment of Hyperphenylalaninaemia in Adults & Children With Phenylketonuria
Express News | RPT-EMA Says Tepezza (Teprotumumab) Received Positive Opinion From Chmp for Treatment of Adults With Moderate to Severe Thyroid Eye Disease
Express News | RPT-EMA Says Chmp Recommends Conditional Marketing Authorisation for Duvyzat (Givinostat), as Treatment for Dmd in Patients From Age Six Who Can Walk
Express News | Corrected-EMA Says Chmp Will Re-Examine (Not 'requested Re-Examination of') Opinion Adopted for Marketing Authorisation Holder for Kisunla (Donanemab)
Express News | EMA Says Chmp Recommended Granting Conditional Marketing Authorisation for Ziihera (Zanidatamab)
Express News | Jazz Pharmaceuticals Showcases Transformative Data at Asco 2025, Highlighting Advances in Small Cell Lung Cancer, Her2+ Gastroesophageal Cancer and Diffuse Glioma
TD Cowen Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $205
Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025
Jazz Pharmaceuticals Completes $935 Million Acquisition of Chimerix
News On Chimerix Inc. (CMRX) Now Under JAZZ
Express News | Jazz Pharmaceuticals Completes Acquisition of Chimerix
A Closer Look At Jazz Pharmaceuticals Plc's (NASDAQ:JAZZ) Uninspiring ROE
Needham Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $210
Jazz Pharmaceuticals Price Target Maintained With a $210.00/Share by Needham